DSIP

What is it?

DSIP stands for delta sleep-inducing peptide, also called emideltide. It is a nine-amino-acid peptide investigated for sleep regulation. Interest centers on falling asleep more easily and improving sleep quality, including deep sleep. It is not an FDA-approved insomnia medicine. [1]

How does it work?

The name comes from early animal research involving slow brain-wave activity during sleep. Scientists have explored effects on sleep and stress signaling, but a clear human mechanism has not been established. A detailed review questioned whether the synthetic peptide studied in experiments is identical to the naturally occurring material originally detected in animals. Describing DSIP as a proven replacement for the body's own sleep signal goes beyond that evidence. [2]

Does it improve sleep?

There are small human studies, and their findings differ. In a 1981 double-blind crossover experiment, six healthy volunteers received DSIP or placebo. Researchers reported more sleep during a short daytime observation period and improvements in some measures of the following night's sleep. This supports further investigation, but six volunteers observed briefly cannot establish a reliable treatment for chronic insomnia. [3]

A 1992 double-blind study enrolled 16 people with chronic insomnia, with eight receiving DSIP and eight placebo over three treatment nights. Some objective measures favored DSIP, but the effects were weak and partly attributable to changes in the placebo group. Participants' subjective sleep quality did not improve. The authors judged a major short-term therapeutic benefit unlikely. [4]

These findings do not establish that DSIP reliably increases restorative deep sleep. Sleep duration, time to fall asleep, sleep stages, and feeling rested are different outcomes. The older trials were small and short, and FDA's 2026 assessment considered the insomnia evidence preliminary and inconclusive. [1,3,4]

What about safety?

The human studies do not establish long-term safety. FDA highlights uncertainty around immune reactions and peptide impurities or aggregation in injectable products. An absence of obvious problems in a tiny study does not establish that a differently manufactured product or route is safe. [1]